Glycoconjugates for glucose transporter-mediated cancer-specific targeting and treatment

Junjie Fu; Jiaxin Yang; Peter H Seeberger; Jian Yin

doi:10.1016/j.carres.2020.108195

Glycoconjugates for glucose transporter-mediated cancer-specific targeting and treatment

Carbohydr Res. 2020 Dec:498:108195. doi: 10.1016/j.carres.2020.108195. Epub 2020 Nov 12.

Authors

Junjie Fu¹, Jiaxin Yang¹, Peter H Seeberger², Jian Yin³

Affiliations

¹ Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, PR China.
² Biomolecular Systems Department, Max Planck Institute of Colloids and Interfaces, Potsdam, 14476, Germany.
³ Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, 214122, PR China. Electronic address: jianyin@jiangnan.edu.cn.

PMID: 33220603
DOI: 10.1016/j.carres.2020.108195

Abstract

First observed in 1920s, the Warburg effects have inspired scientists to harness the unique glucose metabolism of cancer cells for targeted therapy for a century. Carbohydrate-drug conjugates are explicitly designed for selective uptake by cancer cells overexpressing glucose transporters. We summarize the progress in developing glycoconjugates for cancer-specific targeting and treatment over the past decade (2010-2020) and point to some future directions in this field.

Keywords: Anticancer drugs; Glucose transporter; Glycoconjugate; Targeted delivery.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Glucose Transport Proteins, Facilitative / metabolism*
Glycoconjugates / pharmacology*
Glycoconjugates / therapeutic use
Humans
Molecular Targeted Therapy / methods*
Neoplasms / drug therapy*
Neoplasms / metabolism

Substances

Antineoplastic Agents
Glucose Transport Proteins, Facilitative
Glycoconjugates